Evidence map›Paper›PMID 35450871›Full record

ArticleBMJ open diabetes research & care2022

EarLy Surveillance for Autoimmune diabetes: protocol for a qualitative study of general population and stakeholder perspectives on screening for type 1 diabetes in the UK (ELSA 1).

Lauren Marie Quinn, David Shukla, Sheila Margaret Greenfield, Tim Barrett, Joanna Garstang, Felicity Boardman, Ian Litchfield, Colin Dayan, Christine Gardner, Clair Connop and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open diabetes research & care, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Children's Understanding of Risk for Type 1 Diabetes: The TEDDY Study.Clinical diabetes : a publication of the American Diabetes Association · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Lauren Marie QuinnInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.ORCID 0000-0003-0500-4417
David ShuklaInstitute of Applied Health Research, University of Birmingham, Birmingham, UK.
Sheila Margaret GreenfieldInstitute of Applied Health Research, University of Birmingham, Birmingham, UK.
Tim BarrettInstitute of Child Health, University of Birmingham, Birmingham, UK.
Joanna GarstangBirmingham Community Healthcare NHS Trust, Birmingham, UK.
Felicity BoardmanDivision of Health Sciences, Warwick Medical School, Warwick, UK.
Ian LitchfieldInstitute of Applied Health Research, University of Birmingham, Birmingham, UK.
Colin DayanSchool of Medicine, University of Cardiff, Cardiff, UK.
Christine GardnerINVOLVE co-applicant, Birmingham, UK.
Clair ConnopINVOLVE co-applicant, Birmingham, UK.
Amanda LepleyINVOLVE co-applicant, Birmingham, UK.
Parth NarendranInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK p.narendran@bham.ac.uk.ORCID 0000-0002-4583-8793
University of Birmingham · GBBirmingham Community Healthcare NHS Trust · GBCardiff University · GBUniversity of Warwick · GB

Funding

Department of Health
6 · The paper itself

Abstract

objectiveType 1 diabetes (T1D) is the most common form of diabetes in children, accounting for 96% of cases, with 29 000 children affected in the UK. Studies have recently identified immunotherapies that safely delay the development of T1D for at least 3 years, and further therapies are in development. General population screening programs in other countries can now accurately identify children with presymptomatic T1D who can be entered into prevention studies. The UK does not have such a system in place. We aim to explore whether parents and children in the UK would want to be part of such a program of testing for T1D in the general population, how they would want to be informed and participate in such a program, and how any barriers to recruitment and participation can be addressed. Additionally, the views of stakeholders who would be involved in the testing program will be collected and analyzed. RESEARCH DESIGN AND

methodsWe will interview parents/guardians and children aged 3-13 years about their views on screening for T1D. We will recruit purposefully to ensure representation across ethnicities and socioeconomic groups. Interviews will be transcribed, analyzed and used to inform iterative co-design work with additional families to address any issues raised. Similar qualitative work will be undertaken with professional stakeholders who would be involved in implementing any future screening program. Where possible, all aspects of this study will be performed remotely by phone or online to minimize infection risk.

conclusionsThis qualitative study will provide the first insights into acceptability of testing and monitoring for T1D in the general population from the perspective of families and stakeholders in the UK. Co-design work will help establish the barriers and identify strategies to mitigate and overcome these issues, as an important step towards consideration of national testing for T1D.

Indexed as

Diabetes Mellitus, Type 1ChildHumansQualitative ResearchUnited Kingdomantibodiesdiabetes mellitus, type 1prediabetic statequalitative research

Identifiers

PMID35450871
PMCPMC9024254
OpenAlexW4224241174

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.